INTRODUCTION
Multiple myeloma has served as a model of neoplastic disease in both mouse and man. Investigations of mouse myeloma first demonstrated the quantitative relationship between concentration of serum myeloma proteins and tumor weight (1) . Studies of the pathologic immunoglobulins of myeloma (paraproteins) have added substantially to the understanding of the structure, function, and metabolism of normal immunoglobulins and antibodies. Immunoglobulin G (IgG) represents the most abundant normal serum immunoglobulin, and paraproteins of the IgG class occur in over 50% of patients with myeloma (2, 3) . The extreme homogeneity of these paraproteins provides evidence that these products are This work was presented in part at the national meeting of the American Federation for Clinical Research, Atlantic City, N. J., May 1969.
Received for publication 23 December 1969. secreted by the progeny of a single neoplastic cell clone ("monoclonal gammopathy") (4) . Detailed studies of the metabolism of IgG in vivo (5-7) provide useful background for the present investigations, in which quantitative measurements of the total body IgG synthesis rate in vivo and the average myeloma cell IgG synthesis rate in vitro were used to estimate numbers of tumor cells in patients with IgG myeloma. Tumor cell number was then related to the clinical evaluation of extent of disease, and was also used to estimate the average rate of growth of this disseminated human malignancy.
METHODS
Patients. 10 patients with IgG multiple myeloma were selected for study. The diagnosis was established by (a) the presence of an electrophoretically homogeneous serum paraprotein in a concentration greater than 2.0 g/100 ml, which could be typed immunologically as IgG with a single lightchain type, in association with markedly reduced levels of normal immunoglobulin components; (b) the clinical findings of a marrow plasmacytosis of greater than 20%, often with atypical plasma cells; and (c) one or more additional signs of myeloma, such as hypercalcemia, lytic bone lesions, soft tissue plasmacytomas, anemia, Bence Jones proteinuria, renal insufficiency, or amyloidosis. At the time the metabolic studies were done, skeletal roentgenograms were obtained and the extent of bone damage was determined by the Department of Radiology at this institution; involvement was classified in order of increasing severity as: normal bone, osteoporosis, lytic lesions, or extensive skeletal destruction and major fractures. Clinical and laboratory data on the patients selected for these initial studies are shown in Table   I . Severity ranged from those who were newly diagnosed to those with far advanced myelomatosis. Patients L. M., Antisera employed for gel diffusion and immunoelectrophoresis included horse anti-human serum (Hyland Laboratories, Los Angeles, Calif.), as well as anti-IgG, -IgA, -IgM, -kappa, and -lambda raised in rabbits (8) . Primate (10) ; the preparations made with this method were dialyzed against pH 7.3 PBS1 at 100C, normal human albumin was added to prevent damage due to self-irradiation, and the preparations were sterilized by filtration. The preparations were over 97%o precipitable, were calculated to have less than one atom of iodine per molecule of protein, and were pyrogen free.
For the in vitro inhibition radioimmunoassay procedure, higher specific activity (over 10 /ACi/jsg) IgG-l1I was prepared with a modification of the chloramine-T method of Hunter and Greenwood (11 (7) . In addition, the catabolic rate of normal IgG is assumed to be the same as the catabolic rate for the IgG paraproteins of the patients studied.
In vntro studies. In vitro studies of plasma cell IgG synthesis were performed with methods that we have detailed elsewhere (13) . All tissue culture media and supplements were obtained from Grand Island Biological Co., Berkeley, Calif. A 10 ml specimen of bone marrow was aspirated aseptically into a syringe containing heparin. The red cells were sedimented with 3.0 ml of 3% dextran, and the supernatant plasma, which contained the marrow cells, was transferred to a sterile, 50 cc graduated centrifuge tube. The leukocyte-rich plasma was diluted to 45 ml with HBSS-FCS and centrifuged for 10 min at 600 g at room temperature. The cell button was then suspended in 45 ml of HBSS-FCS and centrifuged again under the same conditions. This washing procedure was done six times to reduce the quantity of human IgG in the supernatant plasma to less than 100 ng/ml. After the sixth wash, the cell button was suspended in 3 ml of HBSS-FCS, white blood cells were counted, and viability was assessed (trypan blue exclusion). The cell preparations were free of clumping and viability at the completion of the washings was from 98 to 100%. Slides for microscopic examination were prepared with the Shandon cytocentrifuge and were stained with Wright's stain for a 600-cell differential count. All marrow cells which were morphologically in the lymphoid-plasma cell series were defined as myeloma cells (13) .
After the marrow cells were counted, they were centrifuged one last time to establish a "zero time," and resuspended in minimal essential medium (Spinner's) at a concentration of from 0.5 to 3.0 X 106 cells per ml. The medium was supplemented with 15% FCS, and combined with final concentrations of 50 U of penicillin, 50 ,ug of streptomycin, 2 U of heparin, 0.29 mg of glutamine, and 2.2 mg of sodium bicarbonate per ml of medium. Duplicate 3.0-ml cultures were prepared in 16-X 125-mm screw-cap culture tubes, treated briefly with 5% C02 in air, and incubated at 37°C. Multiple samples were harvested at intervals up to 20 hr by centrifugation at 600 g for 10 min at 10°C. Initial viability was 95 ±2%o; after 18 hr it was 73 +6%. The supernatant medium was decanted and frozen for radioimmunoassay of IgG. The cell pellet was washed twice by resuspension in 10 ml of 0.15 M NaCl followed by centrifugation, and then it was frozen. Before immunoassay, the pellet was suspended in 3.0 ml of 0.15 M saline and sonicated.
IgG radioimmunoassay. An inhibition radioimmunoassay (the "sandwich" solid phase radioimmunoassay), which employs specific antibody bound to a disposable plastic tube (14) , was used for measurement of IgG in the time-culture supernatants and cell sonicates. This assay technique is specific for the heavy-chain determinants of IgG; the sensitivity range is from 10 to 500 ng/ml. In these studies, the patient's own paraprotein was used as the quantitative reference standard for the assay. The characteristics of this assay system render it suitable for recognition of partial identity Total Tumor Cell Number in IgG Myeloma Total body IgG metabolism. The results of the in vivo IgG metabolic studies, summarized in Table I , are similar to data previously reported on IgG turnover in multiple myeloma by other investigators (7, 15, 16) . The half-time of disappearance (t) of IgG-1'5I ranged from 11.6 to 17 days in the myeloma patients. In three control subjects with normal serum IgG levels, the ti ranged from 20 to 24 days, with FCR of 5.2-6.4% of the plasma compartment per day. The average IgG turnover rate in the myeloma patients was 0.34 g/kg per day, approximately 10 times the average rate observed in control subjects. As noted by other investigators (5) (6) (7) 17) , the FCR for IgG was higher in subjects with higher serum IgG concentrations. The total body IgG synthetic rates of our patients could not be correlated with the individual variables of plasma cell morphology, disease duration or extent, or cellular synthetic rate.
Myeloma cell number. The total myeloma cell numbers for the 10 patients studied (Table I) fell within a relatively narrow range (0.5 to 3.1 X 10's cells). Tumor cell number appeared to correlate better with degree of bone damage, as seen on skeletal X-rays, than with any other clinical manifestation of the disease. The four patients who had normal bones or osteoporosis had an average total body myeloma cell mass of 0.88 ±0.45 X 10' myeloma cells, while the six patients with advanced osteolytic bone lesions had 2.75 ±0.37 X 1013 malignant cells (P = < 0.01). The two patients with soft tissue plasmacytomas (D. R. and M. P.) were both in the high tumor cell mass range.
Percentage of bone marrow myeloma cells varied in general with variation in myeloma cell mass, but was not always consistent on repeated aspirates. Inasmuch as cellular synthetic rate was calculated from the total in vitro myeloma cell number rather than from myeloma cell percentage, cell mass determinations were reproducible despite this variation in cell percentage.
The two patients with the lowest serum paraprotein concentrations had the smallest total number of myeloma cells, but in all other instances, the serum paraprotein level could not be related to the absolute size of the malignant cell mass. Patient J. U., who had a hyperviscosity syndrome, deserves specific mention in this regard; although she had the highest concentration and turnover rate of paraprotein of the entire patient group, she also had the highest cellular IgG synthetic rate. In her case, the very high cellular rate of IgG synthesis appears to explain the high serum level.
Similarly, the rates of total body and cellular IgGmp synthesis taken independently did not correlate directly with extent of skeletal disease, and only the quotient of these two rates (myeloma cell number) was significantly related to this clinical manifestation. Hypercalcemia and heavy Bence Jones proteinuria were more common in the group of patients with advanced skeletal disease and high myeloma cell number. DISCUSSION The calculations of human myeloma cell mass reported in this paper must be considered approximate, and must be viewed in the context of present knowledge of the myeloma cell and of IgG metabolism. The prototype myeloma cell is well differentiated with an extensive endoplasmic reticulum and a high capacity for protein synthesis. In some patients, heavy-and light-chain synthesis is "balanced" and only an intact immunoglobulin is secreted (13) ; in other patients, secretion of lightchains is excessive and synthesis unbalanced, leading to Bence Jones proteinuria. The serial in vitro studies reported on here indicate that the cellular synthetic rate for intact IgG by a given clone may be fixed at a certain level for extended periods of time.
The majority of the cellular IgG synthetic rates measured fell within a narrow range, with 9 of the 10 patients having in vitro synthetic rates of from 5 to 14 pg/myeloma cell per day. The range of myeloma cell IgG synthesis rates for these patients is similar to those measured by Nathans, Fahey, and Potter for mouse myeloma (1), and to those estimated by Nossal and Mdkeli for normal, antibody-producing plasma cells in the rat (18) . With our present in vitro assay systems, similar studies could be carried out on myeloma cells which synthesized IgG at rates as low as 0.3 X 1012 g/cell per day, or on bone marrow samples containing as few as 0.5-1.0% myeloma cells which synthesized at a normal rate for myeloma cells. In the latter situation, which might pertain during remission, the relative errors in differential counts of bone marrow cells would be larger, and the resultant cellular synthetic rates would be less accurate.
Recent studies by Morell, Terry, and Waldmann (17) (19) . In IgA myeloma, because of the relatively fixed IgA catabolic rate (7, 20, 21) , changes in the serum concentration would be anticipated to reflect the changes in cell mass more directly.
It should be emphasized that the calculations of tumor cell number depend upon two critical assumptions which are intrinsically difficult to prove: the average rate of IgG synthesis in vitro is assumed to be a valid reflection of the cellular IgG synthesis rate which would be attained in vivo; in addition, the myeloma cells sampled are assumed to be representative of the total body's population of myeloma cells. The reproducibility of results from serial studies of any single patient's cells tends to support the latter assumption, as does the result of a comparative in vitro study of cells from a patient who was not included in the present series because in vivo studies were not done. Specimens were obtained from this patient with far advanced IgG myeloma 2 wk before his death; a 15% plasmacytosis was present in the peripheral blood, and these cells had virtually the same IgG synthetic rate as did his marrow myeloma cells, which were studied simultaneously.
By considering these studies of myeloma cell mass in conjunction with characteristic clinical observations, certain aspects of the natural history of IgG myeloma can be clarified. At the time of the clinical diagnosis, the myeloma cell mass appears to be at least 0.5 X 10' cells, or 0.5 kg of tumor (assuming 101 myeloma cells equal 1.0 kg), indicating that there is an enormous preclinical "iceberg," with prolonged tumor proliferation occurring asymptomatically. Recognition of paraproteins on serum electrophoresis is difficult below concentrations of 0.5 g/100 ml, which would correspond to a myeloma cell mass of approximately 5 X 1010 or about 50 g of tumor. Unless such a mass is localized and symptomatic, early diagnosis is virtually impossible in this disorder.
In our myeloma cell studies, a correlation could be made between the extent of lytic bone disease and tumor cell mass. Patients with far advanced lytic lesions and multiple pathological fractures had more myeloma cells than those who had osteoporosis or normal bones. It is recognized that this correlation may not always hold; in some cases, extraskeletal involvement may be extensive while bones are relatively spared (22 In acute leukemia, clinical manifestations are thought to be due to the number of neoplastic cells in the host. This conclusion has been derived primarily from quantitative studies of leukemia in mice, where progression of leukemia from a single transplanted cell can be characterized with a first-order kinetic model (23) . In the experimental plasmacytoma of the hamster, fatal disease has also been induced after transplantation of a single isolated malignant cell (24) . In man, first-order kinetics can be used to explain the rate of leukemic cell repopulation as measured by duration of unmaintained drug-induced remission (25) . In attempting to construct a hypothetical model of the natural history of human multiple myeloma, we assume first-order kinetics of proliferation for the human monoclonal myeloma cell. By comparing tumor cell mass in newly diagnosed patients with that seen in patients with advanced disease, it appears that the tumor goes through approximately four doublings in size to a mass of up to 3 X 10' cells (about 5% of body weight) at the time of death.
Based on the average magnitude of decline in the serum concentration of IgG paraproteins in patients who show objective response to chemotherapy with alkylating agents (26) , it appears that such therapy usually reduces the cell mass by less than 1 log. Such responses, when maintained with chemotherapy, are associated with an approximate doubling in life expectancy (26) . The average life expectancy from time of diagnosis in untreated myeloma patients (27) Although the assumption of a constant growth rate provides a means for approximating disease duration in myeloma, it may not be the optimal model. In certain solid tumors, growth slows when the tumor becomes large (24) . This form of tumor growth is described better with a Gompertzian growth curve (24, 29) than with a first-order kinetic model. The Gompertzian model would yield shorter estimates of total duration of myeloma if growth slows significantly before diagnosis or early in the period of clinical observation. Serial tumor mass measurements in selected patients may indicate which model of tumor growth is applicable to this disorder.
